A challenge in the treatment of Staphylococcus aureus infections is the high prevalence of
methicillin-resistant S. aureus (MRSA) strains and the formation of non-growing, dormant
'persister'subpopulations that exhibit high levels of tolerance to antibiotics,, and have a role
in chronic or recurrent infections,. As conventional antibiotics are not effective in the
treatment of infections caused by such bacteria, novel antibacterial therapeutics are urgently
required. Here we used a Caenorhabditis elegans–MRSA infection screen to identify two�…

A challenge in the treatment of Staphylococcus aureus infections is the high prevalence of
methicillin-resistant S. aureus (MRSA) strains and the formation of non-growing,
dormant'persister'subpopulations that exhibit high levels of tolerance to antibiotics and have
a role in chronic or recurrent infections. As conventional antibiotics are not effective in the
treatment of infections caused by such bacteria, novel antibacterial therapeutics are urgently
required. Here we used a Caenorhabditis elegans-MRSA infection screen6 to identify two�…